Advertisement
UK markets closed
  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     
  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     
  • AIM

    789.87
    +6.17 (+0.79%)
     
  • GBP/EUR

    1.1628
    +0.0017 (+0.15%)
     
  • GBP/USD

    1.2531
    +0.0007 (+0.06%)
     
  • Bitcoin GBP

    48,346.17
    -1,348.55 (-2.71%)
     
  • CMC Crypto 200

    1,259.29
    -98.71 (-7.27%)
     
  • S&P 500

    5,223.28
    +9.20 (+0.18%)
     
  • DOW

    39,521.06
    +133.30 (+0.34%)
     
  • CRUDE OIL

    78.37
    -0.89 (-1.12%)
     
  • GOLD FUTURES

    2,372.40
    +32.10 (+1.37%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     

Is Gilead Sciences a Buy After Its Disappointing Q2 Results?

Is Gilead Sciences a Buy After Its Disappointing Q2 Results?

Gilead Sciences (NASDAQ: GILD) beat Wall Street estimates when the big biotech announced its first-quarter results in late April. Last week, Gilead announced second-quarter results that were below analysts' expectations. Gilead has been in the news quite a bit in recent months thanks to the clinical success for its COVID-19 therapy remdesivir.